Citations

Mayo Clinic

Showing 10 of 108522 citations.

Percutaneous Clinical T 1a Renal Mass Ablation in the Octogenarian and Nonagenarian: Oncologic Outcomes and Morbidity
Miller, Andrew , Schmit, Grant D. , Weisbrod, Adam J. , Boorjian, Stephen A. , Thompson, R. Houston, Lohse, Christine M. , Kor, Darryl J., Callstrom, Matthew R. , Atwell, Thomas D. , Miller, Andrew J. , Kurup, A. Nicholas

Journal of Endourology | November 11, 2014 | Volume: 29 | Issue: 6 | Pages: 671-676

10.1089/end.2014.0733 | PMID 25386995 Get It

Is 40 the new 30?
Watt, Kymberly D.

Transplant International | November 11, 2014 | Volume: 28 | Issue: 2 | Pages: 146-147

10.1111/tri.12487 | PMID 25385551 Get It

Large‐Scale Gene‐Centric Analysis Identifies Polymorphisms for Resistant Hypertension
Fontana, Vanessa , McDonough, Caitrin W. , Rouby, Nihal M. El, Sá, Ana Caroline C., Chen, Y.‐D. Ida, Gums, John G. , Chapman, Arlene B. , Pepine, Carl J. , Johnson, Julie A. , Turner, Stephen T. , Gong, Yan , Taylor, Kent D. , Chapman, Arlene B. , Cooper‐DeHoff, Rhonda M.

Journal of the American Heart Association | November 11, 2014 | Volume: 3 | Issue: 6 | Pages: No page available

10.1161/jaha.114.001398 | PMID 25385345 Get It

Background Resistant hypertension (RHTN), defined by lack of blood pressure (BP) control despite treatment with at least 3 antihypertensive drugs, increases cardiovascular risk compared with controlled hypertension. Yet, there are few data on genetic variants associated with RHTN. Methods and Results We used a gene‐centric array containing ≈50 000 single‐nucleotide polymorphisms (SNPs) to identify polymorphisms associated with RHTN in hypertensive participants with coronary artery disease (CAD) from INVEST‐GENES (the INnternational VErapamil‐SR Trandolapril STudy—GENEtic Substudy). RHTN was defined as BP≥140/90 on 3 drugs, or any BP on 4 or more drugs. Logistic regression analysis was performed in European Americans (n=904) and Hispanics (n=837), using an additive model adjusted for age, gender, randomized treatment assignment, body mass index, principal components for ancestry, and other significant predictors of RHTN. Replication of the top SNP was conducted in 241 European American women from WISE (Women's Ischemia Syndrome Evaluation), where RHTN was defined similarly. To investigate the functional effect of rs12817819, mRNA expression was measured in whole blood. We found ATP2B1 rs12817819 associated with RHTN in both INVEST European Americans ( P ‐value=2.44×10 −3 , odds ratio=1.57 [1.17 to 2.01]) and INVEST Hispanics ( P =7.69×10 −4 , odds ratio=1.76 [1.27 to 2.44]). A consistent trend was observed at rs12817819 in WISE, and the INVEST‐WISE meta‐analysis result reached chip‐wide significance ( P =1.60×10 −6 , odds ratio=1.65 [1.36 to 1.95]). Expression analyses revealed significant differences in ATP2B1 expression by rs12817819 genotype. Conclusions The ATP2B1 rs12817819 A allele is associated with increased risk for RHTN in hypertensive participants with documented CAD or suspected ischemic heart disease. Clinical Trial Registration URL: www.clinicaltrials.gov ; Unique identifiers: NCT00133692 (INVEST), NCT00000554 (WISE).
Endoscopic ultrasound‐guided pancreatic duct drainage
Fujii‐Lau, Larissa L., Levy, Michael J.

Journal of Hepato-Biliary-Pancreatic Sciences | November 11, 2014 | Volume: 22 | Issue: 1 | Pages: 51-57

10.1002/jhbp.187 | PMID 25385528 Get It

Abstract Endoscopic ultrasound (EUS) has evolved from a purely diagnostic procedure to one with therapeutic capabilities. One of the most challenging therapeutic intervention for endosonographers is EUS‐guided pancreatic drainage. The development of this technique has allowed access and drainage of the main pancreatic duct after failed endoscopic retrograde pancreatography and can avoid invasive procedures such as surgical and percutaneous interventions. This review discusses the indications, technique, challenges, and an algorithmic approach to EUS‐guided pancreatic drainage.
Identification of Independent Primary Tumors and Intrapulmonary Metastases Using DNA Rearrangements in Non–Small-Cell Lung Cancer
Aubry, Marie-Christine, Harris, Faye R. , Halling, Geoffrey C. , Johnson, Sarah H. , Terra, Simone , Drucker, Travis, Kipp, Benjamin R. , Yi, Eunhee S. , Peikert, Tobias, Vasmatzis, George , Wigle, Dennis A. , Drucker, Travis M, Asiedu, Michael K. , Murphy, Stephen J. , Yang, Ping

Journal of Clinical Oncology | November 11, 2014 | Volume: 32 | Issue: 36 | Pages: 4050-4058

10.1200/jco.2014.56.7644 | PMID 25385739 Get It

Purpose Distinguishing independent primary tumors from intrapulmonary metastases in non–small-cell carcinoma remains a clinical dilemma with significant clinical implications. Using next-generation DNA sequencing, we developed a chromosomal rearrangement–based approach to differentiate multiple primary tumors from metastasis. Methods Tumor specimens from patients with known independent primary tumors and metastatic lesions were used for lineage test development, which was then applied to multifocal tumors. Laser capture microdissection was performed separately for each tumor. Genomic DNA was isolated using direct in situ whole-genome amplification methodology, and next-generation sequencing was performed using an Illumina mate-pair library protocol. Sequence reads were mapped to the human genome, and primers spanning the fusion junctions were used for validation polymerase chain reaction. Results A total of 41 tumor samples were sequenced (33 adenocarcinomas [ADs] and eight squamous cell carcinomas [SQCCs]), with a range of three to 276 breakpoints per tumor identified. Lung tumors predicted to be independent primary tumors based on different histologic subtype did not share any genomic rearrangements. In patients with lung primary tumors and paired distant metastases, shared rearrangements were identified in all tumor pairs, emphasizing the patient specificity of identified breakpoints. Multifocal AD and SQCC samples were reviewed independently by two pulmonary pathologists. Concordance between histology and genomic data occurred in the majority of samples. Discrepant tumor samples were resolved by genome sequencing. Conclusion A diagnostic lineage test based on genomic rearrangements from mate-pair sequencing demonstrates promise for distinguishing independent primary from metastatic disease in lung cancer.
Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Databas
Shi, Qian , Gramont, Aimery de , Grothey, Axel, Zalcberg, John , Chibaudel, Benoist , Seymour, Michel , Adams, Richard , Saltz, Leonard B. , Goldberg, Richard M. , Punt, Cornelis J.A. , Douillard, Jean‐Yves , Hoff, Paulo M. , Hecht, J. Randolph, Hurwitz, Herbert I. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Fuchs, Charles S. , Souglakos, John , Falcone, Alfredo , Tournigand, Christophe , Kabbinavar, Fairooz F. , Heinemann, Volker , Bokemeyer, Carsten , de Gramont, Aimery, Schmoll, Hans‐Joachim , Seymour, Matthew T, Saltz, Leonard, Hecht, Joel Randolph, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, Buyse, Marc , Cutsem, Eric Van , Sargent, Daniel J. , Saltz, Leonard , Shi, Qian , Falcone, Alfredo , Seymour, Matthew T , Zalcberg, John , Adams, Richard , Chibaudel, Benoist

Journal of Clinical Oncology | November 11, 2014 | Volume: 33 | Issue: 1 | Pages: 22-28

10.1200/jco.2014.56.5887 | PMID 25385741 Get It

PurposeProgression-free survival (PFS) has previously been established as a surrogate for overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC treatment has advanced in the last decade with extended OS, this surrogacy requires re-examination.MethodsIndividual patient data from 16,762 patients were available from 22 first-line mCRC studies conducted from 1997 to 2006; 12 of those studies tested antiangiogenic and/or anti–epidermal growth factor receptor agents. The relationship between PFS (first event of progression or death) and OS was evaluated by using R2statistics (the closer the value is to 1, the stronger the correlation) from weighted least squares regression of trial-specific hazard ratios estimated by using Cox and Copula models.ResultsForty-four percent of patients received a regimen that included biologic agents. Median first-line PFS was 8.3 months, and median OS was 18.2 months. The correlation between PFS and OS was modest (R2, 0.45 to 0.69). Analyses limited to trials that tested treatments with biologic agents, nonstrategy trials, or superiority trials did not improve surrogacy.ConclusionIn modern mCRC trials, in which survival after the first progression exceeds time to first progression, a positive but modest correlation was observed between OS and PFS at both the patient and trial levels. This finding demonstrates the substantial variability in OS introduced by the number of lines of therapy and types of effective subsequent treatments and the associated challenge to the use of OS as an end point to assess the benefit attributable to a single line of therapy. PFS remains an appropriate primary end point for first-line mCRC trials to detect the direct treatment effect of new agents.
Filling a critical practice gap: experience with a dermatology day treatment center at Mayo Clinic
Storan, Eoin R. , McEvoy, Marian T., Wetter, David A. , Bridges, Alina G. , Camilleri, Michael , Davis, Mark D. P. , el‐Azhary, Rokea A. , Davis, Mark D.P.

International Journal of Dermatology | November 11, 2014 | Volume: 54 | Issue: 5 | Pages: 600-604

10.1111/ijd.12617 | PMID 25384998 Get It

AbstractBackgroundIntensive treatment options are lacking for patients with severe skin disease recalcitrant to outpatient therapy. The availability of inpatient dermatology care has almost disappeared in many parts of the United States. One possible solution for this is a day treatment center for patients with severe dermatologic disease recalcitrant to outpatient therapy.MethodsDescriptive study based on retrospective medical record review of all patients attending the day hospital for treatment in 2010. We collected data on patient demographics, distribution of admission diagnosis, treatments used, and length of stay.ResultsA total of 211 patients had 235 admissions. Mean age was 57.7 years (range 3.8–92.1 years). The most common indications for admission were dermatitis (139 admissions [59.2%]), psoriasis (58 [24.7%]), and mycosis fungoides (eight [3.4%]). The main treatment interventions were wet dressings (195 admissions [83.0%]) and Goeckerman treatment (38 [16.2%]). The median number of days of treatment was three (interquartile range, 2–5 days) for wet dressings and 22 days (interquartile range, 21–24 days) for Goeckerman therapy.ConclusionsThe dermatology day treatment center provided intensive skin‐directed therapy and filled a critical practice gap in the management of our patients with severe widespread skin diseases recalcitrant to outpatient therapy. We propose that the dermatology day treatment center is a valuable model that could be considered by both private practitioners and academic centers in the United States as an important adjunct to fill the gap in availability of intensive topical treatments for patients with severe skin disease.
Experience of a year of adult hospital dermatology consultations
Storan, Eoin R. , McEvoy, Marian T., Wetter, David A. , Camilleri, Michael , Bridges, Alina G. , Davis, Mark D. P. , El-Azhary, Rokea A, el‐Azhary, Rokea A. , Davis, Mark D.P.

International Journal of Dermatology | November 11, 2014 | Volume: 54 | Issue: 10 | Pages: 1150-1156

10.1111/ijd.12555 | PMID 25384904 Get It

AbstractBackgroundDermatology consultations are frequently requested by inpatient hospital services. As inpatient dermatology services in the USA decline, dermatology hospital consultations are becoming increasingly important.ObjectivesWe aim to describe the spectrum of skin diseases encountered and the health care subspecialties requesting dermatology hospital consultations.MethodsWe performed a retrospective chart review of adult patient (age: ≥18 years) dermatology hospital consultations from January 1 to December 31, 2010. We examined patient demographic characteristics, consultation requesting services, and consultation diagnoses.ResultsAmong dermatology services, 614 patients had 674 separate inpatient dermatology consultations during 2010. Of these patients, 55.9% were male (mean age: 59 years). In total, 205 consultations (30.4%) were requested by the internal medicine subspecialty, 137 (20.3%) by the hematology and oncology subspecialty, and 93 (13.8%) by the surgical subspecialty. The most common conditions seen by the hospital dermatology consulting service were skin infections (n = 125, 18.5%), dermatitis (n = 120, 17.8%), drug eruptions (n = 87, 12.9%), chronic wounds and ulcers (n = 55, 8.1%), cutaneous neoplasms (n = 39, 5.8%), graft‐versus‐host disease (n = 37, 5.5%), ecchymosis, purpura simplex or petechia (n = 26, 3.8%), intertrigo (n = 21, 3.1%), and urticaria (n = 20, 3.0%).ConclusionsThe majority of consultations conducted by the dermatology hospital consulting service were for the management of common skin diseases, such as cutaneous infections, dermatitis, and drug eruptions. Most consultations were requested by the departments of internal medicine, hematology and oncology, and surgical services.
Interobserver variability of aneurysm morphology: discrimination of the daughter sac
Suh, Sang Hyun , Cloft, Harry J. , Han, Kyunghwa , Kallmes, David F. , Huston, John

Journal of NeuroInterventional Surgery | November 11, 2014 | Volume: 8 | Issue: 1 | Pages: 38-41

10.1136/neurintsurg-2014-011471 | PMID 25385747 Get It

Objective Several definitions have been proposed to distinguish the daughter sac when treating unruptured intracranial aneurysms. The aim of this study was to evaluate interobserver variability of aneurysm morphology, including the daughter sac, using criteria from the International Study of Unruptured Intracranial Aneurysms (ISUIA) and the Unruptured Cerebral Aneurysm Study of Japan (UCAS). Materials and methods After approval by the institutional review board, we analyzed three morphological features (daughter sac, lobulation, and irregular margin) from the ISUIA and UCAS using angiographic images from 102 saccular aneurysms. Four independent readers interpreted each morphological criterion using dichotomized scales (existence or not). The κ statistic was used to measure interobserver agreement, and κ>0.6 was considered substantial agreement. Results For discrimination of the daughter sac, interobserver agreement among the four readers was substantial using the UCAS criteria (k=0.626 for two-dimensional (2D) and 0.659 for three-dimensional (3D) images) but not for the ISUIA criteria (k=0.487 for 2D and 0.473 for 3D images; significant difference). Irrespective of the images used, pairwise pooled κ values for the UCAS were >0.6, except for one case (score of 0.54 between readers A and B). Regarding the proportion of positive reads, there was a significant difference between reads for the daughter sac using the UCAS and ISUIA criteria. Conclusions For discrimination of the daughter sac, the UCAS definition showed a higher reliability than the ISUIA. However, a further prospective study is necessary to validate this definition as the treatment standard for unruptured intracranial aneurysms.
Ageing and neurotrophic signalling effects on diaphragm neuromuscular function
Greising, Sarah M. , Ermilov, Leonid G., Sieck, Gary C. , Mantilla, Carlos B. , Sieck, Gary , Mantilla, Carlos B

The Journal of Physiology | November 11, 2014 | Volume: 593 | Issue: 2 | Pages: 431-440

10.1113/jphysiol.2014.282244 | PMID 25630263 Get It

Key points Sarcopenia of the diaphragm muscle, i.e. loss of muscle force and size with increasing age, may contribute to respiratory impairment in old age but the exact mechanisms underlying this are currently unknown. Across the lifespan in mice there is worsening neuromuscular function of the diaphragm muscle, specifically reduced force and impaired neuromuscular transmission. We tested the hypothesis that age‐related changes to the diaphragm muscle depend on brain‐derived neurotrophic factor (BDNF), acting through its high affinity receptor. BDNF improves neuromuscular transmission in the diaphragm muscle into early old age, but not older ages. Inhibition of BDNF signalling impairs neuromuscular transmission only in young adult mice. Our results suggest that the loss of endogenous BDNF precedes reduced activity of the high affinity receptor tropomyosin‐related kinase receptor B in the ageing mouse diaphragm muscle. Abstract The age‐related mechanisms underlying sarcopenia are largely unknown. We hypothesize that age‐related neuromuscular changes depend on brain‐derived neurotrophic factor (BDNF) acting through the tropomyosin‐related kinase receptor B (TrkB). Maximal specific force and neuromuscular transmission failure were assessed at 6, 18 and 24 months following control, BDNF or phosphoprotein phosphatase 1 derivative (1NMPP1) treatment in male TrkB F616A mice. Phosphoprotein phosphatase‐1 derivatives such as 1NMPP1 inhibit TrkB kinase activity as a result of this single amino acid mutation in the ATP binding domain. Maximal twitch and isometric tetanic force were reduced at 24 months compared to 6 and 18 months ( P < 0.001). Neuromuscular transmission failure significantly increased at 18 and 24 months compared to 6 months (age × treatment interaction: P < 0.001). Neuromuscular transmission was improved following BDNF at 6 and 18 months and was impaired only at 6 months following 1NMPP1 treatment. Age and inhibition of TrkB kinase activity had similar effects on neuromuscular transmission failure, supporting a critical role for BDNF/TrkB signalling on neuromuscular changes in ageing. These results suggest that an age‐related loss of endogenous BDNF precedes reductions in TrkB kinase activity in the diaphragm muscle.